| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PHRS.2009.10.002 |
| P8608 | Fatcat ID | release_tvyjraogwnhihiazxmpy4iiffq |
| P932 | PMC publication ID | 2880921 |
| P698 | PubMed publication ID | 19840853 |
| P5875 | ResearchGate publication ID | 38021906 |
| P50 | author | Mikko Airavaara | Q42635702 |
| Brandon K. Harvey | Q64867341 | ||
| P2093 | author name string | Seung T Lim | |
| P2860 | cites work | HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses | Q24312224 |
| Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus | Q24523073 | ||
| Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps | Q24533013 | ||
| Adeno-associated virus vector integration | Q24624120 | ||
| Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis | Q24630353 | ||
| The GDNF family: signalling, biological functions and therapeutic value | Q28216478 | ||
| Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons | Q28241378 | ||
| HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain | Q37439341 | ||
| Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain | Q37517550 | ||
| A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180. | Q37687787 | ||
| Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. | Q39596516 | ||
| Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. | Q39607095 | ||
| Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted | Q39642143 | ||
| The nerve growth factor 35 years later | Q39667849 | ||
| A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines | Q39685433 | ||
| Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease | Q39863620 | ||
| Adenovirus type 11 uses CD46 as a cellular receptor | Q39864028 | ||
| Construction of adenovirus vectors through Cre-lox recombination | Q39878424 | ||
| Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1 | Q40065369 | ||
| MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. | Q40095787 | ||
| Seizure suppression by GDNF gene therapy in animal models of epilepsy | Q40154016 | ||
| Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease | Q40197232 | ||
| Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus | Q40281192 | ||
| Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates | Q40339968 | ||
| Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. | Q40347828 | ||
| Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. | Q40387759 | ||
| Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons | Q28274311 | ||
| Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 | Q28303765 | ||
| AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 | ||
| Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration | Q28581577 | ||
| In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 | ||
| A third-generation lentivirus vector with a conditional packaging system | Q29616120 | ||
| Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo | Q29616612 | ||
| Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections | Q31457974 | ||
| Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer | Q33296224 | ||
| Expanded-capacity adenoviral vectors--the helper-dependent vectors | Q33544035 | ||
| A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears | Q33640285 | ||
| Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats | Q33745707 | ||
| In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. | Q33782356 | ||
| Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins | Q33783411 | ||
| Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery | Q33786060 | ||
| AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. | Q33791830 | ||
| Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion | Q33943282 | ||
| Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation | Q34113268 | ||
| Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo | Q34277742 | ||
| Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis | Q34304615 | ||
| Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery | Q34351483 | ||
| Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats | Q34436780 | ||
| Adeno-associated virus vectors can be efficiently produced without helper virus | Q34479933 | ||
| AAV hybrid serotypes: improved vectors for gene delivery | Q34619573 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 | ||
| Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. | Q34664932 | ||
| Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease | Q34695123 | ||
| Development and applications of non-HIV-based lentiviral vectors in neurological disorders | Q34902118 | ||
| Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy | Q35131218 | ||
| Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for ch | Q35161530 | ||
| Lentiviral vectors for treating and modeling human CNS disorders | Q35880080 | ||
| Update on herpesvirus amplicon vectors | Q35903203 | ||
| Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo | Q35948485 | ||
| ??? | Q64821040 | ||
| Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production | Q40413793 | ||
| Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats | Q40427208 | ||
| Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease | Q40442685 | ||
| Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. | Q40462605 | ||
| Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. | Q40464992 | ||
| Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. | Q40532718 | ||
| AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease | Q40560840 | ||
| Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector | Q40568114 | ||
| Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins | Q40583034 | ||
| Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). | Q40613492 | ||
| Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease | Q40633580 | ||
| HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. | Q40637488 | ||
| Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. | Q40643169 | ||
| Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system | Q40675429 | ||
| Glial cell line-derived neurotrophic factor modulates kindling and activation-induced sprouting in hippocampus of adult rats | Q40686200 | ||
| Insect cells as a factory to produce adeno-associated virus type 2 vectors | Q40690831 | ||
| Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. | Q40710699 | ||
| Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. | Q40723341 | ||
| Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. | Q40723600 | ||
| Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease | Q40737427 | ||
| Adenovirus-mediated glial cell line-derived neurotrophic factor gene delivery reduces motor neuron injury after transient spinal cord ischemia in rabbits | Q40737759 | ||
| Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector | Q40741282 | ||
| Systematic determination of the packaging limit of lentiviral vectors | Q40776442 | ||
| Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration | Q40805293 | ||
| Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration | Q40811477 | ||
| Rescue of ischemic brain injury by adenoviral gene transfer of glial cell line-derived neurotrophic factor after transient global ischemia in gerbils | Q40839243 | ||
| Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage | Q40841418 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Pharmacologic treatment of cognition in Alzheimer's dementia | Q40850299 | ||
| Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. | Q40870371 | ||
| Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. | Q40874496 | ||
| Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease | Q40904090 | ||
| Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. | Q40905804 | ||
| Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis | Q40935559 | ||
| Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. | Q40983409 | ||
| Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain | Q41090635 | ||
| Dopaminergic neurons protected from degeneration by GDNF gene therapy | Q41128316 | ||
| Role of T cells in inflammation caused by adenovirus vectors in the brain. | Q41187652 | ||
| Nerve growth factor and the neurotrophic factor hypothesis | Q41188098 | ||
| Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons | Q41433192 | ||
| Nerve growth factor treatment after brain injury prevents neuronal death | Q41478262 | ||
| Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders | Q41543685 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons | Q42435326 | ||
| Trophic factor effects on septal cholinergic neurons. | Q42469153 | ||
| Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons | Q42478941 | ||
| Nerve growth factor in Alzheimerʼs disease: defective retrograde transport to nucleus basalis | Q42481313 | ||
| Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration | Q42485030 | ||
| NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats | Q42492745 | ||
| Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration | Q42503374 | ||
| Distribution of [125I]nerve growth factor in the rat brain following a single intraventricular injection: correlation with the topographical distribution of trkA messenger RNA-expressing cells | Q42505941 | ||
| Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. | Q42520774 | ||
| Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections | Q42525515 | ||
| Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells | Q42616240 | ||
| Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial | Q42650874 | ||
| Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 | ||
| AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment | Q43704735 | ||
| Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression | Q43839045 | ||
| Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. | Q44213139 | ||
| Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum | Q44631221 | ||
| Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer | Q44694208 | ||
| Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination | Q44907561 | ||
| Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system | Q45007196 | ||
| Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. | Q45245677 | ||
| Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease | Q45292300 | ||
| Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease | Q45304363 | ||
| Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. | Q45387438 | ||
| Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain | Q45420843 | ||
| Stroke and TGF-beta proteins: glial cell line-derived neurotrophic factor and bone morphogenetic protein. | Q36020135 | ||
| Viral vector strategy for glial cell line-derived neurotrophic factor therapy for stroke | Q36251160 | ||
| Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease | Q36288717 | ||
| Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications | Q36366788 | ||
| Adenoviral vectors--how to use them in cancer gene therapy? | Q36419822 | ||
| Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS | Q36491424 | ||
| Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells | Q36506251 | ||
| Delivery of large genomic DNA inserts >100 kb using HSV-1 amplicons. | Q36512694 | ||
| Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. | Q36541150 | ||
| Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. | Q36561684 | ||
| Neurotrophic factors and amyotrophic lateral sclerosis | Q36565607 | ||
| Angels and demons: neurotrophic factors and epilepsy. | Q36630307 | ||
| Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder | Q36630501 | ||
| Transduction of brain by herpes simplex virus vectors | Q36681937 | ||
| Production and characterization of adeno-associated viral vectors | Q36779416 | ||
| Use of nonintegrating lentiviral vectors for gene therapy | Q36831097 | ||
| Nerve growth factor gene therapy in Alzheimer disease | Q36838863 | ||
| Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease | Q36969309 | ||
| Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery | Q37076735 | ||
| Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point | Q37082159 | ||
| The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors | Q37090137 | ||
| Ex vivo and in vivo gene delivery to the brain | Q37144385 | ||
| A human trial of HSV-mediated gene transfer for the treatment of chronic pain | Q37195741 | ||
| GDNF therapy for Parkinson's disease | Q37203371 | ||
| Cellular immune response to cryptic epitopes during therapeutic gene transfer | Q37250034 | ||
| Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector | Q37251114 | ||
| Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. | Q37283186 | ||
| Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys | Q37301013 | ||
| Real-time MR imaging of adeno-associated viral vector delivery to the primate brain | Q37313954 | ||
| Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity | Q37331730 | ||
| Non-integrating lentiviral vectors. | Q37347158 | ||
| Clinical application of lentiviral vectors - concepts and practice | Q37347167 | ||
| Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys | Q37399627 | ||
| Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection | Q37410352 | ||
| Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 | ||
| Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors | Q45727079 | ||
| Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons | Q45751217 | ||
| Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. | Q45831294 | ||
| Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice | Q45856784 | ||
| Improvement of spatial learning and memory after adenovirus-mediated transfer of the nerve growth factor gene to aged rat brain | Q45858011 | ||
| Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain | Q45866495 | ||
| CD46 is a cellular receptor for group B adenoviruses | Q45869560 | ||
| Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain | Q45874048 | ||
| Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors | Q45881242 | ||
| A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease | Q45883058 | ||
| Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease | Q47695139 | ||
| Changes in brain cholinesterases in senile dementia of Alzheimer type | Q48176243 | ||
| Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys | Q48197305 | ||
| Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor | Q48208108 | ||
| Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys | Q48325968 | ||
| Continuous infusion of neurotrophin-3 triggers sprouting, decreases the levels of TrkA and TrkC, and inhibits epileptogenesis and activity-dependent axonal growth in adult rats | Q48437842 | ||
| Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). | Q48570524 | ||
| Exogenous NGF affects cholinergic transmitter function and Y-maze behavior in aged Fischer 344 male rats | Q48677998 | ||
| Specific tropism of HIV-1 for microglial cells in primary human brain cultures | Q48920198 | ||
| Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. | Q50869517 | ||
| Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. | Q51659718 | ||
| Human nerve growth factor improves spatial memory in aged but not in young rats. | Q52057103 | ||
| Update on adenovirus and its vectors | Q64380348 | ||
| Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group | Q73966063 | ||
| Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo | Q75702642 | ||
| A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group | Q77114422 | ||
| A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III) | Q77398255 | ||
| Oncolytic virus therapy using genetically engineered herpes simplex viruses | Q81549503 | ||
| P433 | issue | 1 | |
| P921 | main subject | vector-borne disease | Q2083837 |
| gene therapy | Q213901 | ||
| neurodegeneration | Q1755122 | ||
| P304 | page(s) | 14-26 | |
| P577 | publication date | 2009-10-17 | |
| P1433 | published in | Pharmacological Research | Q15724622 |
| P1476 | title | Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS | |
| P478 | volume | 61 |
| Q39139260 | AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. |
| Q34420401 | AAV-mediated targeting of gene expression to the peri-infarct region in rat cortical stroke model |
| Q45303314 | Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype |
| Q37186189 | Assembly of protein-based hollow spheres encapsulating a therapeutic factor |
| Q34997042 | Autofluorescent cells in rat brain can be convincing impostors in green fluorescent reporter studies |
| Q37019334 | Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain |
| Q92749606 | Biomimetic Materials and Their Utility in Modeling the 3-Dimensional Neural Environment |
| Q98178405 | Brain-Derived Neurotrophic Factor (BDNF) Preserves the Functional Integrity of Neural Networks in the β-Amyloidopathy Model in vitro |
| Q35729655 | C3 peptide promotes axonal regeneration and functional motor recovery after peripheral nerve injury |
| Q37121244 | CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. |
| Q39446547 | Cell replacement therapy is the remedial solution for treating Parkinson's disease |
| Q35685561 | Cell-type specific expression of oxytocin and vasopressin genes: an experimental odyssey |
| Q27340137 | Cell-type specific expression of the vasopressin gene analyzed by AAV mediated gene delivery of promoter deletion constructs into the rat SON in vivo |
| Q31049117 | Cell-type specific oxytocin gene expression from AAV delivered promoter deletion constructs into the rat supraoptic nucleus in vivo |
| Q39197908 | Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease |
| Q38256020 | Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector |
| Q33824159 | Current status of non-viral gene therapy for CNS disorders |
| Q34473323 | Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease |
| Q36614768 | Differential Cellular Tropism of Lentivirus and Adeno-Associated Virus in the Brain of Cynomolgus Monkey |
| Q36823757 | Diffusion of macromolecules in the brain: implications for drug delivery |
| Q38073181 | Drug delivery systems for the treatment of ischemic stroke |
| Q30424484 | Drug delivery to the brain by focused ultrasound induced blood-brain barrier disruption: quantitative evaluation of enhanced permeability of cerebral vasculature using two-photon microscopy |
| Q36694301 | Exercise leads to the re-emergence of the cholinergic/nestin neuronal phenotype within the medial septum/diagonal band and subsequent rescue of both hippocampal ACh efflux and spatial behavior |
| Q40077177 | Gene Manipulation Strategies to Identify Molecular Regulators of Axon Regeneration in the Central Nervous System |
| Q36939767 | Gene Transfer of Brain-derived Neurotrophic Factor (BDNF) Prevents Neurodegeneration Triggered by FXN Deficiency |
| Q33917592 | Gene delivery with viral vectors for cerebrovascular diseases |
| Q38166648 | Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications |
| Q50050924 | Human Neural Stem Cells with GDNF Site-Specific Integration at AAVS1 by Using AAV Vectors Retained Their Stemness |
| Q38383483 | Inorganic nanovectors for nucleic acid delivery |
| Q40670785 | Long-term expression of miRNA for RNA interference using a novel vector system based on a negative-strand RNA virus |
| Q51173482 | Low-Intensity Pulsed Ultrasound Enhances Nerve Growth Factor-Induced Neurite Outgrowth through Mechanotransduction-Mediated ERK1/2-CREB-Trx-1 Signaling. |
| Q91733486 | MRI-Guided Focused Ultrasound for Targeted Delivery of rAAV to the Brain |
| Q26773485 | Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease |
| Q36157573 | MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis |
| Q42839842 | Microarray analysis of transcriptome of medulla identifies potential biomarkers for Parkinson's disease |
| Q35088011 | Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS. |
| Q26750915 | Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins |
| Q26777286 | Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools |
| Q33636631 | New small molecules for the treatment of Parkinson's disease |
| Q52559939 | Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process. |
| Q26824184 | Parkinson's disease: gene therapies |
| Q37957674 | Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis |
| Q36590070 | Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models |
| Q45875097 | Spinal Cord Molecular and Cellular Changes Induced by Adenoviral Vector- and Cell-Mediated Triple Gene Therapy after Severe Contusion. |
| Q38073714 | Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein |
| Q45857176 | Tandem Delivery of Multiple Therapeutic Genes Using Umbilical Cord Blood Cells Improves Symptomatic Outcomes in ALS. |
| Q63990333 | Tetrahedral DNA nanostructures facilitate neural stem cell migration via activating RHOA/ROCK2 signalling pathway |
| Q38438132 | The use of an adeno-associated viral vector for efficient bicistronic expression of two genes in the central nervous system |
| Q42200227 | Transduction efficiency of neurons and glial cells by AAV-1, -5, -9, -rh10 and -hu11 serotypes in rat spinal cord following contusion injury |
| Q50350373 | Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats. |
| Q34078114 | Widespread cortical expression of MANF by AAV serotype 7: localization and protection against ischemic brain injury |
Search more.